Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Study offers 'real hope' for C.diff sufferers
Stomach pain
In the US alone, almost 500,000 C.diff infections occurred in 2011, resulting in 29,000 deaths.
Harmless spores of C.diff prevent repeated infection

Giving spores of non-toxic Clostridium difficile (C.diff) by mouth is effective in stopping bouts of C.diff infection, according to a study published in The Journal of American Medical Association.
 
C.diff infection is a type of bacterial infection that affects the digestive system. It most commonly affects those who have been treated with antibiotics.

Symptoms include severe diarrhoea, a high temperature and painful abdominal cramps.

Lead author Dale Gerding, professor of medicine at Loyola University Medical Centre (LUMC), Chicago, said: "Results of this study confirm findings of earlier studies that showed that if we can establish non-toxic C.diff as a resident of the gut of the patient, that we can protect the patient from infection by the toxic strains of C.diff.”

He adds that the results are worthy of further study to confirm that treatment with non-toxic C.diff spores can reduce recurrent C.diff infection and prevent a first episode of C.diff infection in those who are taking any antibiotics and are at high risk of infection.

Dale Gerding and an international team of infectious disease researchers ran trials on 173 adult patients.  Of those assigned non-toxic C.diff in liquid form, 11 per cent experienced a repeat infection within 42 days, compared with 30 per cent of those given a placebo - showing a significant reduction.

Hospital acquired infections, including C.diff, are an increasing problem throughout the world. In the US alone, almost 500,000 C.diff infections occurred in 2011, resulting in 29,000 deaths.

Stuart Johnson, infectious disease specialist at LUMC, said that the study offers 'real hope' for those debilitated by recurring bouts of the infection.

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.